Table 1

Immune-mediating agents other than neoepitope vaccines show induction of neoepitope-specific T cells correlating with clinical responses

AgentDiseaseReference
Bintrafusp alfa
(α-PD-L1, TGF-βRII)
HPVneg SCCHNRedman et al,
Journal of Clinical Investigation, 132:e161400, 2022
α-PD-1+α-CTLA4Advanced salivary
gland cancer
Vos et al, Nature Medicine, 29:3077–89, 2023
α-PD-L1Metastatic urothelial
carcinoma
Holm et al, Nature Communications, 13:1935, 2022
α-CTLA4Prostate cancerSubudhi et al, Science Translational Medicine, 12:eaaz3577, 2020
Adoptive transfer vaccine primed autologous T cells+autologous
DC tumor cell lysate vaccine+bevacizumab
Recurrent ovarian cancerBobisse et al, Nature Cancer, 4:1410–7, 2023
Allo-tumor cells (XRT)+GM-CSF+BCGMelanomaPodaza et al, Frontiers in Immunology, 11:1147, 2020
MAGE vaccineMelanomaCorbiere et al, Cancer Research, 71:1253–62, 2011
Autologous DC tumor cell lysate vaccine+bevacizumab±low-dose cyclophosphamideRecurrent ovarian cancerTanyi et al, Science Translational Medicine, 10:eaao5931, 2018
α-PD-1+α-CTLA4NSCLC, melanomaMcGranahan et al, Science 351:1463–9, 2016
α-PD-1NSCLCRizvi et al, Science, 348:124–8, 2015
  • BCG, Bacille Calmette-Guérin; CTLA4, cytotoxic T-lymphocyte associated protein 4; DC, dendritic cells; GM-CSF, granulocyte-macrophage colony-stimulating factor; HPVneg SCCHN, human papillomavirus negative squamous cell carcinoma of the head and neck; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; PD-L1, programmed death-ligand 1; TGF, transforming growth factor; XRT, external beam radiation therapy.